Home › Funds › Cormorant Asset Management, LP › PBLS
Cormorant Asset Management, LP position in PBLS
PARABILIS MEDICINES INC · Health Care
Cormorant Asset Management, LP reported holding 4,615,612 shares of PBLS (PARABILIS MEDICINES INC) in its Q3 2026 13F filing — a position valued at US$149.0M, representing 10.66% of its reported portfolio and ranking #1 among its reported holdings. Cormorant Asset Management, LP has disclosed PBLS holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Cormorant Asset Management, LP's PBLS position evolved
Cormorant Asset Management, LP first disclosed a stake in PBLS in Q2 2026 at 4,615,612 shares (US$126.3M). The position peaked in Q3 2026 at 4,615,612 shares, worth US$149.0M. Across 2 filings, Cormorant Asset Management, LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 4,615,612 shares valued at US$149.0M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 4.62M | $126.33M | New |
| Q3 2026 | 4.62M | $149.04M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PBLS and 13F data
PBLS (PARABILIS MEDICINES INC) is a Health Care company. 129 other funds we track also report a position in PBLS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$942.2M), ARCH Venture Management, LLC (US$207.1M), venBio Partners LLC (US$170.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PBLS
- RA CAPITAL MANAGEMENT, L.P. 29.18M sh · $942.16M · Q3 2026
- ARCH Venture Management, LLC 6.41M sh · $207.07M · Q3 2026
- venBio Partners LLC 5.27M sh · $170.06M · Q3 2026
- Alphabet Inc. 4.92M sh · $158.85M · Q3 2026
- Nextech Invest Ltd. 4.66M sh · $150.57M · Q3 2026
- REGENERON PHARMACEUTICALS, INC. 4.17M sh · $134.54M · Q3 2026
- Siren, L.L.C. 2.99M sh · $96.62M · Q3 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 2.37M sh · $76.47M · Q3 2026
- Frazier Life Sciences Management, L.P. 2.33M sh · $75.26M · Q3 2026
- Farallon Capital Management 2.37M sh · $64.82M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.88M sh · $60.73M · Q3 2026
- Soleus Capital Management, L.P. 1.68M sh · $54.39M · Q3 2026
More on Cormorant Asset Management, LP
FAQ
How long has Cormorant Asset Management, LP held PBLS?
Cormorant Asset Management, LP has disclosed PBLS holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Cormorant Asset Management, LP's current position in PBLS?
As of Q3 2026, Cormorant Asset Management, LP holds 4.62M shares of PBLS (PARABILIS MEDICINES INC), valued at $149.04M, representing 10.66% of its reported portfolio and ranking #1.
Has Cormorant Asset Management, LP been buying or selling PBLS?
In the latest 13F filing (Q3 2026), Cormorant Asset Management, LP held unchanged its position in PBLS. The position peaked in Q3 2026 at 4.62M shares.
Which other funds hold PBLS?
Other major institutional holders of PBLS include RA CAPITAL MANAGEMENT, L.P., ARCH Venture Management, LLC, venBio Partners LLC, among 129 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.